Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Sheon Karol Joins West Lane Partners as Senior Advisor

West Lane Partners

West Lane Partners, a private equity firm focused on special situations in middle market companies spanning healthcare, tech, financial services and industrials, is pleased to announce that Sheon Karol, a nationally recognized investment banker and restructuring advisor, has joined the firm as a Senior Advisor. Mr. Karol brings over three decades of experience in investment banking, restructuring, and senior corporate leadership, with deep expertise in complex M&A, capital raises, and operational turnarounds. Skilled in de-risking situations, he brings a flexible yet disciplined approach that favors iterative decision-making over rigid or binary choices. His ability to surface a range of strategic options, often under pressure, has made him a trusted advisor to owners navigating both opportunity and uncertainty. His contributions to the field have earned national recognition, including the “Boutique Investment Banker of the Year” award from the Atlas Awards. “Sheon and I have been in the trenches together on complex deals. He’s masterful at aligning stakeholders, cutting through noise, and adapting in real time to keep transactions on course. Where others see roadblocks, he sees possibility—and responds with clarity and flexibility,” said Deryck Palmer, Founder and Managing Partner at West Lane Partners. “His dynamic approach, experience, and deep market insight into the industries on which we’re focused, and an instinct for what owners value most, makes him an exceptional addition to our firm.” “I think of the middle market as the river less fished” said Mr. Karol. “Middle market companies are often overlooked, undercapitalized, and underserved by institutional talent. At West Lane Partners, our focus on investments between $25 million and $75 million is about more than deal size—it’s about bringing high-caliber insight to businesses at pivotal moments and tailoring strategic options to match the evolving goals of owners and the realities of the market. The result is not just getting deals done, but generating long-term value others might miss.” Mr. Palmer added, “I’ve always been impressed by Sheon’s expertise, creativity, positivity and determination to get the best for his clients. These qualities enable him to inexorably bring difficult situations to their best possible conclusion and there are few who bring such capabilities to the middle market.” About Sheon Karol Mr. Karol has advised on high-stakes transactions across a myriad of industries in the middle market, including manufacturing, biotech, pharma, for-profit education, medical research, agriculture, consumer goods, food & grocery, sports, and technology. Mr. Karol has successfully executed a wide range of strategic transactions, including M&A advisory, capital raises, and restructurings, for both healthy and distressed businesses and their stakeholders. He has also served in executive capacities, including as Chief Restructuring Officer of a $1 billion company, for which he renegotiated the company's debt and avoided a bankruptcy filing. Many of Mr. Karol’s transactions, including Violin Memory and Peekay Boutiques, have won awards. He served as SVP of Winn-Dixie and managed the company's sale of assets in excess of $200 million and the disposition of 326 stores (in a 90-day period); guided the auction and sale of Farmland’s nitrogen fertilizer business that exceeded the “stalking horse” bid by $25 million; advised the CRO in the sale of the Texas Rangers baseball team; and advised foreign buyers in their U.S. expansion. Trustee positions include the Violin Memory and Lily Robotics Trusts. A middle market M&A thought leader, he writes and lectures widely, including on entrepreneurship, auction theory, sale processes, the middle market and foreign buyers. He holds FINRA SIE, Series 63 and Series 79 certifications. Mr. Karol received a J.D. from Yale Law School and a B.A. from Yeshiva College. About West Lane Partners West Lane Partners is a private equity firm whose senior leadership has over 150 years of collective restructuring and private equity experience working with underperforming, stressed and distressed companies across a range of industries in both large cap and middle market companies. In addition to providing capital, the firm combines decades of restructuring, private equity, legal and financial expertise to collaborate with management in developing and executing bespoke solutions that deliver mutually beneficial outcomes. Contact Details Curtis Johnson, Investor Relations +1 973-404-0999 cjohnson@westlanepartners.com Meir Kahtan Public Relations, LLC Meir Kahtan +1 917-864-0800 mkahtan@rcn.com Company Website https://www.westlanepartners.com

June 11, 2025 10:00 AM Eastern Daylight Time

Medicus Pharma Ltd. (NASDAQ: MDCX) Positioned for Growth in a $5 Trillion Biotech Market

Medicus Pharma Ltd (MDCX)

The global population is aging rapidly, with the number of people aged 65 and older expected to double by 2050. This demographic shift is driving a surge in chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions. At the same time, breakthroughs in biomedical research are enabling the development of targeted, more effective therapies, transforming treatment approaches in both human and veterinary medicine. These twin forces, rising demand fueled by aging and disease prevalence along with technological innovation, are propelling unprecedented growth across biopharma markets. The global biotechnology sector is projected to expand from $1.74 trillion in 2025 to over $5 trillion by 2034, representing a compound annual growth rate (CAGR) of 12.5 percent. Specialty pharmaceuticals, including biologics and novel drug delivery systems, are expected to grow even faster, with forecasts predicting a 26.5 percent CAGR over the same period. Oncology remains a key driver, with spending on cancer medicines forecasted to nearly double from $252 billion in 2024 to $441 billion by 2029. Meanwhile, veterinary oncology is emerging as a high-potential frontier, with the U.S. market alone projected to reach $1.48 billion by 2030, driven by rising pet ownership and demand for advanced care. The urology therapeutics segment also shows steady growth potential, expected to rise from $10.5 billion in 2024 to $15.8 billion by 2033. Amid this expansive and interconnected landscape, Medicus Pharma Ltd. (NASDAQ: MDCX) is methodically positioning itself to capitalize on these powerful market tailwinds. Through a diversified portfolio of innovative drug delivery platforms and targeted therapies, Medicus addresses some of the most pressing health challenges across human and veterinary medicine. Medicus Pharma: Methodically Building a High-Leverage Growth Story Though still flying under many investors’ radars, Medicus Pharma is rapidly assembling the elements of a high-leverage growth story. On June 2, the company completed a $7 million public offering, selling 2,260,000 units at $3.10 each. Each unit includes one common share plus one warrant exercisable at the same price over five years. The capital will primarily fund a Phase 2 proof-of-concept trial in basal cell carcinoma (BCC) using Medicus’s flagship doxorubicin-loaded dissolvable microneedle patch (D-MNA). Additional funds may support broader development in non-melanoma skin cancers or other pipeline programs. Strategic Veterinary Expansion: FDA Submission for Equine Squamous Cell Carcinoma This timely financing was quickly followed by a major regulatory milestone. On June 9, Medicus announced submission of a formal product development plan to the U.S. FDA for a veterinary application of D-MNA targeting equine squamous cell carcinoma (SCC). The program is advancing under an Investigational New Animal Drug (INAD) file, aiming for conditional approval. It leverages the same microneedle patch technology used in human dermatologic trials, demonstrating a strategic effort to repurpose clinical data and technology across human and veterinary markets. Tapping an Untapped Veterinary Oncology Opportunity The equine indication represents a significant market opportunity. As CEO Dr. Raza Bokhari highlighted, “In veterinary medicine, where only a handful of oncology drugs are approved, developing a non-invasive treatment for equine SCC targets a largely unmet need, a potential $250 million market.” The planned study will enroll 50 horses across five U.S. sites in a placebo-controlled design, comparing two D-MNA doses against placebo, with tumor response assessed at day 90. Medicus has secured FDA Minor Use in Major Species (MUMS) Designation, which grants seven years of market exclusivity upon approval, a valuable commercial advantage in a segment with limited competition. D-MNA Platform: Promising Safety and Efficacy Data The D-MNA patch, originally developed for human skin cancers, is supported by encouraging early data. A Phase 1 trial in Australia (SKNJCT-001) involving 13 patients with nodular BCC showed the treatment was well tolerated with no dose-limiting toxicities. Remarkably, 46 percent of lesions achieved complete histological clearance after a single application, an impressive result given the minimally invasive delivery. This platform delivers doxorubicin directly into the dermis through a biodegradable microneedle array, minimizing systemic exposure while concentrating the drug’s effect at the tumor site. Expanding Clinical Trials Across Continents Building on this foundation, Medicus is running two Phase 2 trials. In the U.S., the SKNJCT-003 study recently expanded enrollment from 60 to 90 patients following a positive interim analysis that showed over 60 percent clinical clearance. This multicenter, placebo-controlled trial compares the patch to the standard of care, with European sites now joining due to growing investigator interest. Concurrently, the SKNJCT-004 trial in the United Arab Emirates involves 36 patients across four hospitals, including Cleveland Clinic Abu Dhabi, targeting both histological and clinical clearance endpoints. Strategic Acquisition: Entering Late-Stage Urology Complementing its internal pipeline, Medicus is also positioning itself as a consolidator of high-value assets. In April, the company signed a binding letter of intent to acquire UK-based Antev Ltd., whose lead candidate, Teverelix, is a GnRH antagonist in late-stage development for two urology indications: acute urinary retention (AUR) due to benign prostatic hyperplasia and hormone-sensitive prostate cancer in patients at elevated cardiovascular risk. These combined markets represent a $6 billion annual opportunity, and Teverelix has completed multiple clinical trials in Europe. Under the deal, Antev shareholders would receive approximately 19 percent of Medicus’s post-merger equity, plus up to $65 million in milestone payments tied to regulatory and commercial successes. A Platform With Multiple Growth Levers Together, Medicus offers optionality and platform leverage across human oncology, veterinary medicine, and dermatology, all fields marked by limited innovation and strong pricing power. Its lead asset is already in Phase 2 with international trial sites and active FDA engagement. The veterinary program offers a faster commercialization path with fewer regulatory barriers, while the Antev acquisition could propel Medicus into late-stage, multi-billion-dollar indications. Why Investors Should Watch MDCX Medicus Pharma (NASDAQ: MDCX) paints the picture of a small-cap biotech transitioning from concept to execution. The recent capital raise was non-dilutive and immediately followed by a key regulatory filing. Clinical trials across humans and animals are expanding, and a transformative acquisition is imminent. With a methodical approach tying together clinical progress, intellectual property, and market strategy, Medicus is quietly building momentum, making MDCX a stock to watch closely in the second half of 2025. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by MDCX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

June 10, 2025 10:20 AM Eastern Daylight Time

CURE ALZHEIMER’S FUND APPOINTS TWO NEW MEMBERS TO ITS BOARD OF DIRECTORS

Alzheimer’s Disease Research Foundation

Cure Alzheimer’s Fund, a nonprofit dedicated to advancing research with the highest potential to prevent, slow or reverse Alzheimer’s disease, announced today that Christine Villas-Boas and Brittany Bowlen have been appointed to its Board of Directors. “We are pleased to welcome two new voices to our Board—Christine and Brittany each bring a unique passion and perspective that will help us better serve our mission to fund research aimed at curing Alzheimer’s disease,” said Henry McCance, Board Chair and Co-Founder of Cure Alzheimer’s Fund. “This expansion of our board is a meaningful step forward as we continue to grow thoughtfully and stay focused on making a lasting impact on the fight against this devastating disease.” “Brittany and Christine bring outstanding leadership expertise and a clear passion for our cause,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “Their diverse experience in strategy and commitment to impactful philanthropy will enhance our efforts to accelerate critical research. We’re excited to welcome their insight and energy to our board.” Christine Villas-Boas currently serves as President and Treasurer of the Michel and Claire Gudefin Family Foundation, a leading supporter of Cure Alzheimer’s Fund. Ms. Villas-Boas, a Connecticut College graduate, began her career at Chase Manhattan Bank in 1974, working in U.S. Corporate Banking and International Capital Markets across New York, Paris, and London. She later consulted in credit and corporate finance training. Ms. Villas-Boas also serves on the board of the Learn2Earn Charitable Foundation based in Naples, Florida. Inspired by personal loss—her mother Claire, who died of Alzheimer’s in 2015, and other family members affected by the disease—Christine and the Michel and Claire Gudefin Family Foundation are deeply committed to supporting Cure Alzheimer’s Fund in its mission to find a cure. She became a Trustee in 2021 and joined the Board of Directors in 2025. Brittany Bowlen is a seasoned leader in consulting and professional sports, most recently serving as the Senior Vice President of Strategy for the Denver Broncos. In addition to her professional career, Brittany is deeply committed to driving community impact, currently serving as the Vice Chair of the Board of Directors for Boys & Girls Clubs of Metro Denver and as a member of the Board of Visitors for Duke University’s Fuqua School of Business. She holds a Master of Business Administration (MBA) from Fuqua and a Bachelor of Business Administration (BBA) from the University of Notre Dame’s Mendoza College of Business. Cure Alzheimer’s Fund is a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided 971 grants to more than 300 of the world’s leading researchers and contributed more than $232 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has achieved a 100% perfect score and a Four-Star rating for 13 consecutive years from Charity Navigator. Cure Alzheimer’s Fund also received a Platinum Seal of Transparency from Candid, formerly known as GuideStar. Our Board of Directors, Trustees and a core group of other donors direct their donations to our overhead expenses so that 100% of general donations go to our research program. For more information, visit CureAlz.org. Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org Company Website http://curealz.org

June 03, 2025 08:41 AM Eastern Daylight Time

Inspira Technologies Receives $2 Price Target and Buy Rating: Everything You Need to Know

Global Markets News

Litchfield Hills Research has initiated coverage of Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN)* with a Buy rating and a $2 price target, representing potential upside of over 225% from current trading levels of around $0.61 per share. This bullish outlook comes as the medical technology company continues to critical care technology addressing what the analyst describes as "a medical need without good options." The analyst notes that mechanical ventilators are "WWII technology in desperate need of an upgrade" with reports showing that 30% to 50% of ICU patients don't survive. Unlike mechanical ventilation, Inspira's ART500 technology would enable patients to remain awake during treatment while stabilizing oxygen levels without intubation and coma. What distinguishes Inspira from typical early-stage medical device companies is its proven regulatory execution and early commercial success. The company's first generation technology, the INSPIRA ART100 system, received FDA clearance in May 2024 and is already deployed in leading U.S. hospitals. The excitement around this technology reached a new high in April 2025 when the first successful patient treatment was completed at Westchester Medical Center. The commercial momentum seems to be accelerating. Inspira announced it received payment in the "low hundreds of thousands of dollars" from its U.S. distributor for delivered systems, marking the company's first revenues. CEO Dagi Ben-Noon called this "a transformative milestone for Inspira as we establish our presence in the U.S. medical landscape." The company has now initiated global commercial rollout discussions and expects additional deliveries in the second half of 2025. Central to Inspira's technology platform is the AI-powered HYLA blood sensor, which recently achieved 96% accuracy in clinical studies at Sheba Medical Center, one of the world's top hospitals. The system provides continuous monitoring without requiring blood draws, targeting the blood gas analyzer market projected to reach $5.7 billion by 2030. The analyst identifies massive market opportunities, with the global mechanical ventilators market expected to reach $20.69 billion by 2034. Inspira's flagship INSPIRA ART500 system in development aims to disrupt this market by providing respiratory support through direct blood oxygenation rather than forcing air into damaged lungs. Inspira has established strong intellectual property protection with multiple U.S. patents and novel patent claims protecting its core technologies. The company is executing a strategic approach of securing FDA clearance for individual components before integrating them into comprehensive systems. When comparing Inspira to similar medical device companies, the analyst found the stock trades at significant discounts despite having FDA-cleared technology already treating patients. The $2 price target reflects confidence in the company's ability to capitalize on its early commercial success and expand into the massive mechanical ventilation market. The analyst concludes that Inspira may represents a unique opportunity, combining proven FDA-cleared technology with substantial market opportunity and attractive valuation metrics in the high-growth medical device sector. Recent News from Inspira: Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing * Legal Disclaimer & Disclosure: Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by the Wall Street Wire platform & media network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This article contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire, which includes a monthly fee of five thousand US dollars paid in cash via bank transfer in return for promotional content and distribution services. The operators also receive additional fees for non promotional advisory and data services. Inspira Technologies did not necessarily review or approve this content prior to publication. Please review the full disclaimers and compensation disclosures here which include further details: redditwire.com/terms. We are not responsible for third party analyst price targets or market estimates are refer to them based on publicly availble reports. Additional or competing price target may exist and readers are advised to refer to the full report and its respective disclaimers and disclosures. Contact Details Wall Street Wire Editorial Desk media.globalmarkets@gmail.com

June 02, 2025 09:19 AM Eastern Daylight Time

Centre for Neuro Skills Chief Financial Officer Named 2025 Kern County Heart Walk Chair

Centre for Neuro Skills

Lindsay Ashley, chief financial officer of Centre for Neuro Skills, has been named chair of the American Heart Association ’s 2025 Kern County Heart and Stroke Walk. The annual event is scheduled for Saturday, Oct. 11, at California State University, Bakersfield. “The Kern County Heart and Stroke Walk is an opportunity to celebrate heart disease and stroke survivors, raise lifesaving funds for the American Heart Association and encourage a healthy lifestyle,” said Ashley. “By bringing the community together to raise awareness and funds to fight heart disease and stroke, we’re making strides to ensure our loved ones can live longer, healthier lives.” Ashley will lead a team of Kern County-area executives to recruit companies and organizations to take part in the Heart and Stroke Walk. The leadership team and supporting organizations will raise funds for the American Heart Association while leading action-oriented conversations about employee health, corporate engagement, community health and community transformation. The American Heart Association is the world’s leading non-profit dedicated to a world of healthier lives for all. In addition to Ashley, the 2025 Kern County Heart and Stroke Walk executive leadership team includes: David Harrington, Centre for Neuro Skills Didra Cantu, MPA-HCM, Encompass Health Rehabilitation Hospital George Jenkins, Dignity Health, Bakersfield Memorial Hospital Ken Keller, Dignity Health, Bakersfield Memorial Hospital Kevin Burton, Klein DeNatale Goldner Lindsay Barnes, KGET-TV 17 Lisa Kreber, PhD, CBIS, Adventist Health Bakersfield Scott Salters, Cushman & Wakefield | Pacific Commercial Realty Advisors Sky Newton, SHRM-CP, Valley Strong Credit Union "The Heart and Stroke Walk is a fantastic chance for Kern County to come together as a united community, standing strong against heart disease and stroke," said Kelley Berry, executive director of the American Heart Association, Kern County. "We are immensely grateful for Lindsay's steadfast expertise, passion, and dedication to our mission. Leaders like her are crucial in our ongoing efforts to save lives and provide hope to families affected by heart disease and stroke." Funds raised go toward the American Heart Association’s work to advance lifesaving research, education and health for everyone. In Kern County, the Association has expanded access to CPR skills, connected local heart and stroke patients to the latest science-based treatments through its hospital programs and supported community members managing high blood pressure with tools and resources for better blood pressure control. Heart disease and stroke are largely preventable and how you eat, move and manage stress impacts your well-being, physically and mentally. Participants in the Heart and Stroke Walk gain access to resources, tools and activities to support both mental and physical well-being for employers and employees. Participants can register for the event at BakersfieldHeartWalk.com. Registrants can also create personal fundraising pages, download the Heart Walk mobile app and encourage family and friends to join. Companies interested in participating can contact Kelley Berry at Kelley.berry@heart.org. Centre for Neuro Skills, with seven locations across California and Texas, will be participating in American Heart Association’s local heart walk events across both states. Dr. Matt Ashley, Chief Medical Officer of Centre for Neuro Skills, currently serves as Board President on the Central Texas American Heart Association’s Board of Directors and will transition to Board Chair this July. As a former Heart Walk Chair in Austin, Texas, Dr. Matt Ashley remains committed to participating in and supporting the Central Texas Heart Walks. *** About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with the American Heart Association in Kern County on heart.org/southern-california, Facebook, Instagram, X or by calling 1-800-AHA-USA1. About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. For a video overview of CNS, visit our YouTube channel. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. ### Contact Details Landis Communications Inc. Andie Davis +1 415-766-8355 cns@landispr.com Company Website https://www.neuroskills.com/

May 20, 2025 08:01 AM Pacific Daylight Time

Image

Market Alert: DarioHealth Receives $3 Price Target and Buy Rating: Everything You Need to Know

Global Markets News

Litchfield Hills Research has initiated coverage of DarioHealth Corp. (NASDAQ: DRIO)* with a Buy rating and a $3 price target, representing potential upside of over 350% from current trading levels of around $0.66 per share. This bullish outlook comes as the digital health company continues to transform its business model and expand its comprehensive chronic care platform. DarioHealth has successfully pivoted from a direct-to-consumer model to a B2B2C (business-to-business-to-consumer) approach since 2020. This strategic shift has allowed the company to leverage its consumer platform strengths while expanding sales to health plans and employers. The company's B2B2C recurring revenue grew by an impressive 398% year-over-year in Q4 2024, demonstrating strong market adoption. The analyst highlights Dario's proven track record of both organic growth and strategic acquisitions, including the recent Twill acquisition which has strengthened its multi-condition platform. This expansion has positioned Dario to address five of the most common, expensive chronic conditions through a single, integrated solution. The $3 price target is based on a discounted future earnings model with a 9% discount rate. The analysis assumes Dario will reach GAAP breakeven in the second half of 2026, continue strong revenue growth to reach $66.1 million in 2026, achieve non-GAAP operating income of $17.4 million in 2026, and show improving gross margins, exceeding 80% in its core B2B2C business. Importantly, the report demonstrates that even at the $3 target price, Dario would trade at approximately 2.2x projected 2026 sales, which is still below the peer average of 2.28x. The analyst suggests Dario should command a premium multiple given its high growth profile and comprehensive platform. The report highlights Dario's unique competitive advantages relative to peers in the digital health space. Unlike competitors who focus on single conditions, Dario offers a comprehensive platform addressing diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. When comparing current market cap to sales and enterprise value to sales multiples, Dario trades at substantial discounts – 81% below peers on market cap to sales ratio and 54% below peers on enterprise value to sales ratio. This valuation gap, combined with Dario's proven clinical outcomes and expanding market presence, forms the core of the analyst's bull case. A significant growth driver highlighted in the report is Dario's expansion into the GLP-1 weight management space. The company's research has shown that members using GLP-1 experienced significant reductions in blood glucose levels in the first five months with changes sustained throughout the year. With the GLP-1 market projected to reach $100 billion by 2030, Dario's comprehensive solution combining medication management with behavioral support positions it to capture market share in this rapidly growing segment. Strategic partnerships, including its recent collaboration with Rula Health, further strengthen Dario's offering by providing access to over 15,000 behavioral health providers nationwide. The company is also leveraging AI technology to reduce operating expenses, with projections suggesting a 20% reduction in expenses between Q4 2024 and Q4 2025 through AI-driven process optimization. Litchfield Hills projects Dario's revenue will grow to $35.9 million in 2025 and $66.1 million in 2026, with gross margins improving to nearly 70% by 2026. The company is expected to achieve operational cash flow breakeven by late 2025, with full profitability in the second half of 2026. The recent $25.6 million private placement has strengthened Dario's balance sheet, providing sufficient runway to execute its strategic plan. With a blue-chip client list that includes major employers like Amazon, Microsoft, and Google, as well as top insurers and pharmaceutical companies, Dario appears well-positioned to capitalize on the growing demand for integrated digital health solutions that deliver measurable clinical outcomes and positive ROI. Recent News from Dario: DarioHealth Reports First Quarter 2025 Financial and Operating Results Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives * Legal Disclaimer & Disclosure: Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by the Wall Street Wire platform & media network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This article contains paid promotional content related to DarioHealth and was produced as part of their paid subscription to Wall Street Wire, which includes a monthly fee of five thousand US dollars paid in cash in return for promotional content and distribution services. The operators also receive additional fees for non promotional advisory and data services. DarioHealth did not necessarily review or approve this content prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. We are not responsible for third party analyst price targets are refer to them based on publicly availble reports. Additional or competing price target may exist and readers are advised to refer to the full report and its respective disclaimers and disclosures. Contact Details Wall Street Wire Network media.globalmarkets@gmail.com

May 19, 2025 07:51 AM Eastern Daylight Time

Annual Giant Sequoia Lands Coalition Progress Report Highlights Significant Advances in Emergency Wildfire Recovery, Research and Restoration

Save the Redwoods League

Officials from the State of California, USDA Forest Service, National Park Service, Tule River Indian Tribe of California, Save the Redwoods League and other members of the Giant Sequoia Lands Coalition (GSLC) today announced significant progress in their work to protect the largest trees on Earth from extreme wildfires. In its 2024 progress report, the GSLC confirms coalition partners have conducted restoration activities in more than half of the world’s sequoia groves since 2022, reducing the risk of extreme wildfires and improving overall forest health. “The Giant Sequoia Lands Coalition has made remarkable progress in defending the largest trees in the world from the growing threat of extreme megafires,” said coalition Co-Chair Kevin Conway, state forests program manager for CAL FIRE. “With meticulous research we’re gaining critical insight into the changing dynamics of these fire-adapted ecosystems. Through strategic fuel reduction and other restoration efforts across thousands of acres we’re actively making forests healthier. What began as a shared commitment in the face of crisis has evolved into a deeply rooted collaboration, built on trust, expertise and a commitment to the survival of giant sequoias.” Giant sequoia ecosystems provide essential habitat for wildlife, store vast amounts of carbon, protect headwaters and water quality, support the cultural and spiritual practices of Tribal Nations and anchor a thriving outdoor recreation economy. In the past decade, approximately 20% of the world’s mature giant sequoias died from megafires, primarily during the catastrophic fires of 2020 and 2021. Years of fire exclusion, drought and increasing temperatures were the primary drivers of the severe wildfires that killed these magnificent trees. The GSLC formed in 2022 in the face of this existential crisis. 2024 Highlights from the Report: Scientific Advancements: Leading giant sequoia ecologists published new research on post-fire regeneration and the emerging threats of native bark beetles. The GSLC also launched monitoring efforts to understand the health and vulnerabilities of giant sequoias. Ongoing research and monitoring provide a scientific basis for restoration programs and inform best practices across the sequoia range. Two recent publications discuss the substantial risk of losing portions of giant sequoia groves due to high tree mortality rates and inadequate natural recovery if no intervention is taken. Innovation: In May a health inspection of the world’s largest tree, General Sherman, was organized by GSLC members and led by the National Park Service and Ancient Forest Society. Three different technologies were used in the study, and the tree was found to be in good health. Cultural Burning Returns: Members from the Tule River Indian, North Fork Mono, and Tübatulabal Tribes led two cultural burn demonstrations within a giant sequoia grove, sharing their deep knowledge and raising awareness for this important land stewardship practice. The cultural burns were held at the Alder Creek Grove in collaboration with Save the Redwoods League and other coalition members. Rapid Wildfire Response: During the Coffee Pot Fire in Tulare County in August 2024, the GSLC members mobilized swiftly to protect vulnerable groves in Sequoia National Park and neighboring lands managed by the Bureau of Land Management. Approximately 12 large sequoias were killed by the wildfire, but overall large tree losses were kept to a minimum because of the swift actions of firefighters and the GSLC. The GSLC’s restoration work in 2024 was managed by 1,652 personnel. Since 2022, the GSLC has completed 18,743 acres of restoration treatments in 44 giant sequoia groves, and 8,500 acres of treatments in forests surrounding the groves. Fire exclusion, combined with drought and rising temperatures, has resulted in a hazardous and unnatural buildup of combustible plant materials (fuels) within and surrounding the groves. Restoration work increases the wildfire resilience of the groves by reducing the amount of fuels through manual and mechanical reductions, prescribed fires and cultural burning practices. Without these efforts, the groves are susceptible to wildfires that burn with an intensity that far exceeds the historical fires that giant sequoias evolved with, fires that they need to reproduce and regenerate. More than 74,800 native trees were planted in 2024 within groves to aid in forest recovery, raising the total to more than 617,000 native trees in the last three years. Reforestation projects focus on areas that experienced uncharacteristically high wildfire intensity where seed trees have died, burned seeds were not able to develop and minimal regeneration was naturally occurring. The full report is available here. “The Giant Sequoia Lands Coalition originated in a time of crisis. Today, it is a model for collaboration, restoration, and stewardship based in science and ecocultural knowledge,” said Ben Blom, director of stewardship and restoration for Save the Redwoods League and chair of the GSLC restoration working group. “We are poised to deepen our impact across the range in 2025. We’ve accomplished a lot as a coalition, but the work is far from done. We need to keep our momentum going to protect these irreplaceable American forests at the scale they need to thrive.” “Despite significant progress, the restoration work is far from done. The threats to giant sequoias remain urgent, and restoration at the scale required demands long-term coordination, sustained funding and supportive policies,” continued Blom. The members of the Giant Sequoia Lands Coalition include: California Department of Forestry and Fire Protection (CAL FIRE), stewards of Mountain Home Demonstration State Forest California State Parks, stewards of Calaveras Big Trees State Park National Park Service, represented by Sequoia and Kings Canyon National Parks and Yosemite National Park Tulare County, stewards of Balch Park Tule River Indian Tribe of California, stewards of all or parts of five sequoia groves University of California, Berkeley, stewards of Whitaker’s Forest USDA Forest Service, represented by the Sequoia National Forest, Giant Sequoia National Monument, Sierra National Forest, and Tahoe National Forest U.S. Department of Interior, Bureau of Land Management, stewards of Case Mountain Extensive Recreation Management Area GSLC Affiliate Members: American Forests, Ancient Forest Society, Giant Sequoia National Monument Association, Save the Redwoods League (stewards of a section of the Alder Creek Grove), Sequoia Parks Conservancy, Southern Sierra Conservancy, Stanislaus National Forest, US Geological Survey—Western Ecological Research Center and Yosemite Conservancy. Note to media: Images of GSLC projects and places are available for download here. * * * About Giant Sequoia Lands Coalition The Giant Sequoia Lands Coalition (GSLC) is a landscape-scale, multi-partner collaboration dedicated to the conservation and stewardship of giant sequoia grove ecosystems. Our coalition is composed of all federal, tribal, state and local agencies and organizations that manage giant sequoia groves in public, tribal or private nonprofit ownership. Our affiliate partners include select federal and state conservation agencies, nongovernmental organization conservation groups, and academic research partners with a shared commitment to protect and steward giant sequoias and their ecosystems from emerging threats associated with climate change and the extended absence of natural, low-severity wildfire processes on the landscape. Learn more at giantsequoias.org. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 redwoods@landispr.com Company Website https://giantsequoias.org

May 13, 2025 07:55 AM Pacific Daylight Time

Image

Players Health and MaxU Partner to Power the Next Generation of Mentally Resilient Athletes

Players Health

In a bold move to redefine athlete development, Players Health and MaxU today announced a strategic partnership to bring elite-level mental skills training to youth athletes across North America. Unveiled during Mental Health Awareness Month, this strategic alliance is both timely and purpose-driven. As mental health emerges as a cornerstone of athletic excellence and personal growth, Players Health and MaxU unite around a shared mission: to empower the whole athlete with transformative mindset tools that go beyond the game. Both organizations are anchored in a bold belief—mental health and performance are vital to athlete safety, now and into the future. This partnership integrates MaxU’s groundbreaking mental performance platform directly into the Players Health ecosystem—empowering young athletes with the focus, confidence, and resilience needed to thrive in sports, school, and life. “This is more than a partnership—it’s a movement,” said Dan Greco, Co-Founder of MaxU. “Together, we’re scaling access to proven mental skills training that helps athletes navigate pressure, unlock peak performance, and build habits that last a lifetime.” With a reach spanning teams, schools, and youth organizations, the impact is immediate and scalable—creating a new blueprint for how mental wellness and performance are taught, measured, and mastered in youth sports. “Over the last several years since joining Players Health, I've been focused on creating an environment where every young athlete feels supported in every part of their journey,” said Kyle Lubrano, Chief Athlete Safety Officer of Players Health. “Mental resilience is the foundation for everything else — confidence, physical performance, and long-term success. Partnering with MaxU allows us to deliver real, lasting change for athletes and families everywhere. This allows us to provide kids with the tools to believe in themselves, thrive under pressure, and carry those skills through every stage of life.” Two missions. One movement. Grounded in purpose and fueled by innovation, this alliance between Players Health and MaxU reflects a shared belief: supporting the whole athlete—physically, mentally, and emotionally—is not just the future of youth sports. It’s the standard. Players Health is a sports technology company providing digital risk management services, reporting tools and insurance products to sports organizations to empower them to stay ahead of their ever-changing safety and compliance responsibilities. Working towards establishing the safest environment for athletes, Players Health views the health and safety of athletes as a priority in today's sports landscape. Contact Details Jackson Gaskins playershealth@hotpaperlantern.com MaxU Contact MaxU info@maxu.co Company Website https://www.playershealth.com

May 13, 2025 09:00 AM Eastern Daylight Time

Roberts & Ryan Inc. Welcomes Rear Admiral Matthew Ott (Ret.) to its Advisory Board

Roberts & Ryan, Inc.

Roberts & Ryan Inc., America’s first Service-Disabled Veteran-Owned Broker Dealer, is pleased to announce that Rear Admiral Matthew Ott (Ret.) has joined the firm’s Advisory Board. Mr. Ott is the founder and CEO of Ott and Associates and the firm On Target Together. He is a retired U.S. Navy Rear Admiral, where he served on amphibious assault ships, destroyers, and aircraft carriers and served across all levels of tactical, operational, and strategic warfare. Accomplished in command overseas and in the U.S., his service ranged from Secretary of Defense Staff, Defense Logistics Agency, U.S. Fleet Forces Command, Naval Supply Systems Command, and culminated in his third return to NAVSUP Weapon Systems Support, leading 2,500 team members across three sites, providing global supply chain management functions for 3,900+ aircraft and 300 ships, submarines, and nuclear reactors for the Navy, Marine Corps, and 80 global partners. A decorated 32-year career officer, Ott is a recognized authority on Supply Chain Management, Complex Systems Architecture, bridging Industry and Government, executing Humanitarian and Disaster Response, and creating tough, winning teams. Ott is best known for enhancing the Navy Sustainment System Supply Architecture as its key material director in the 41B strategic scale design of Navy-wide supply chains to run more effectively and affordably. The complex launches covered aviation, maritime, shipyard, maintenance repair and overhaul, nuclear, ordnance and subsistence markets. A Human Centered Design expert, he creates value using real-time visualization and horizontally integrates complex systems. His leadership, coaching, process discipline and refinement allow stakeholders to win in high stakes environments. His teams are creative, action-oriented, accountable, and focused on leveraging untapped potential to unlock value. Ott received a B.A. in Economics and Business from the Virginia Military Institute. He holds an MBA from the University of North Carolina at Chapel Hill with concentrations in Supply Chain Management and E-business and Digital Commerce. He is a distinguished graduate of the National Defense University’s Industrial College of the Armed Forces (ICAF), where he earned an M.S. in National Security and Resource Strategy. Ott is also Vice President, Partnerships and Alliances for Throughline, an Enterprise Strategy and Design firm where he will continue to bring his military ethos to the commercial world. He speaks about lessons learned, applicability of cross-functional approaches, and applies frameworks to complex problems in the defense, commercial, start-up, small business, and NGO spaces. He is available to serve C-Suite advisory level and teams to be On Target Together. For more on his U.S. Navy Background, please visit the U.S. Navy Website. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $2.38 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, focusing primarily on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Securities are offered by Roberts & Ryan Inc., member FINRA | SIPC | MSRB | NYSE | NASDAQ. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

May 12, 2025 09:00 AM Eastern Daylight Time

Image

1 2 3 4 5 ... 239